Back to Search
Start Over
Response rate in cardiac resynchronization therapy patients implanted with a left ventricular quadripolar lead and the MultiPoint™ pacing feature early activated. QUARTO III.
- Source :
-
European journal of clinical investigation [Eur J Clin Invest] 2023 Apr; Vol. 53 (4), pp. e13935. Date of Electronic Publication: 2022 Dec 29. - Publication Year :
- 2023
-
Abstract
- Background: Although cardiac resynchronization therapy (CRT) is beneficial in most heart failure patients, up to 40% do not respond to CRT. It has been suggested that multipoint left ventricle pacing (MPP) would increase the response rate.<br />Aim: To assess the CRT response rate at 6 months in patients implanted with a CRT device with the MPP feature activated early after the implant.<br />Methods: This was a multicentre, prospective, open-label and non-randomized study. The primary endpoint was response to biventricular pacing defined as >15% relative reduction in left ventricular end-systolic volume (LVESV) comparing echocardiography measurements performed at baseline and 6 months by a core laboratory. Among secondary endpoints the combined endpoint of mortality or all-cause hospitalizations was evaluated. Primary study endpoint and clinical outcomes were compared to a Quarto II control cohort.<br />Results: Totally, 105 patients were included. The response rate was 64.6% (97.5% lower confidence bound 53%). Mean relative reduction in LVESV was 25.3%, and mean absolute increase in LVEF was 9.4%. The subjects with device programmed using anatomical approach showed a trend towards higher responder rate than those using the electrical approach (72% vs. 61.1%, p = 0.32). Finally, the combined incidence of mortality and or all-cause hospitalizations at 6 month was 12.4%.<br />Conclusions: Early activation of MPP was not associated to an advantage increasing echocardiography responders to CRT at 6 months of follow-up. Nevertheless, patients programmed using widest pacing cathodes had a numerically higher responder rate. Finally, early activation of MPP was associated to a low incidence of clinical endpoints at 6 months of follow-up.<br /> (© 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)
Details
- Language :
- English
- ISSN :
- 1365-2362
- Volume :
- 53
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- European journal of clinical investigation
- Publication Type :
- Academic Journal
- Accession number :
- 36504276
- Full Text :
- https://doi.org/10.1111/eci.13935